Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 intraperitoneal infusion plus low-dose radiotherapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
ChiCTR2200057704Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (5 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Safety. Started Jan 2022; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200057704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057704.